SmartTRAK is pleased to announce that Joe Mish has been named new VP of Sales and will lead our commercial team. Before joining SmartTRAK two years ago, originally as Director of Sales, Joe had 10+ years experience in medical device sales, with a concentration on Joint Replacement and Spine & Robotic Technologies. Joe sold and implemented analytic software to manage value-based care and bundled payment, working with Stryker, LDR/ZimmerBiomet and Stryker Performance Solutions.

"I couldn't be more pleased to have a true professional with data analytics/IT/SaaS plus medical device background like Joe in this position. I think you will agree that he is the right person to bring SmartTRAK to the next level." - SmartTRAK CEO Sharon O'Reilly

Meet Joe Mish, SmartTRAK's new VP of Sales: 

What do you like about SmartTRAK? I truly love the value we bring to our customers. With the world being so volatile and medical device markets still being disrupted in so many ways, we offer clients a predictable way to stay ahead of their competition. This is extremely rare. There is no better feeling than standing behind a company and product that you really believe in…we are focused and committed to building long term relationships and strategic partnerships with our customers, and it shows.

WW Advanced Wound Care continues to grow in the mid-single-digits as company revenues reflect normalcy in wound care with a likely increase in wound severity.

For Q222, SmartTRAK Financial Dashboard reports the WW Advanced Wound Care (AWC) market grew +6.4%. WW Advanced Dressings and WW Wound Biologics were also up, while NPWT-heavy External Devices revenue increased marginally.

Among the many topics covered in detail in our comprehensive Q222 Advanced Wound Care Market Recap* are:

• Complete Q222 AWC Overview and Highlights
• SmartTRAK's Expert Analysis and Insights
• All Company News including Revenues, Data, Charts and Shares
• Growth Analysis – Currency Having a Significant Impact in Q2

SmartTRAK highlights key movements in the quickly changing landscape of interventional pain management and identifies practice trends surrounding SCS, PNS, minimally invasive spine and SI Joint Fusion from the recent ASPN and INS meetings.

Strong demand for alternatives to narcotic pain management combined with an aging population and growing incidence of chronic pain continue to drive demand for interventional pain techniques. The approach to the treatment of chronic intractable pain is evolving, with a shift toward data-focused treatment optimization, growing use of digital monitoring and holistic evaluation of patient outcomes. Furthermore, increasing overlap among various devices and therapies as well as unclear boundaries between interventional pain, orthopedic and spine practices is spurring physicians to adopt collaborative approaches to patient care.

Among the many timely topics covered in this comprehensive Market Outlook article "Pain Intervention: A Market of Moving Targets", which can be downloaded in its entirety here, are:

Among the many topics covered in detail in our comprehensive Q222 Extremities Market Recap* are:

John Uribe, MD, discusses inset glenoid technology and the future of shoulder replacement

John Uribe, MD, discusses his most recent research and experience with inset glenoids and how inset glenoids could influence the practice of shoulder replacement surgery. Dr. Uribe is a dual board-certified orthopedic surgeon with Baptist Health Group South Florida specializing in sports medicine, arthroscopic surgery and minimally invasive surgical procedures for degenerative knee, shoulder and elbow conditions. He is also the Chair of the Herbert Wertheim College of Medicine, Coral Gables, FL and the team physician for the Florida Panthers hockey team and the Miami Dolphins football team.

Dr. Uribe authored a study published in JSES International reporting results from 39 patients with advanced shoulder arthritis having anatomic shoulder replacement with the OVOMotion Shoulder Arthroplasty System from Anika, a stemless shoulder with an inlay glenoid component. The study demonstrated that treatment with inlay total shoulder arthroplasty resulted in significant functional improvement, pain relief and patient satisfaction at a mean follow-up of 41 months.

To find out more, including Dr. Uribe’s thoughts on the benefits of inlay glenoids vs onlay; the potential acceptance of inlay technology; trends such as the shift to reverse shoulders, site-of-care; and what’s next, click on the video below to listen to the recorded interview (17:36 min). A link to download a complete transcript of the interview is also provided below.

Despite stronger headwinds from slowing elective procedures, supply chain challenges and unfavorable foreign exchange rates, most total joint companies saw positive growth in Q222.

The WW Total Joints Market grew in Q222 despite slowing sequential growth compared to Q122’s growth. A slowdown in elective procedures late in the quarter along with continued supply chain challenges and the effect of foreign exchange rates resulted in stronger headwinds. SmartTRAK notes that several companies reported the carryover of these headwinds into Q3 that could dampen market recovery through year-end.

Among the many topics covered in detail in our comprehensive Q222 Total Joints Market Recap* are:

Michael Chen, MD, the 2022 President of the Society of Neurointerventional Surgery (SNIS) and a neurointerventionalist at Rush University Medical Center in Chicago, discusses advances in stroke care research and innovation in an interview with   SmartTRAK at the SNIS 19 ^th Annual meeting held in Toronto, Ontario, Canada July 25-29, 2022. 

Surgical matrices revenue is flat while procedure volumes level out

With elective procedures in the United States mostly back at pre-pandemic levels, the US Surgical Matrices Market returned to what had been normal growth according to SmartTRAK Financial Dashboard. Becton Dickinson* (BD) grew to a 26.9% share, while AbbVie* slipped to second place.

Among the many topics covered in detail in our comprehensive Q222 US Surgical Matrices Market Recap* are:

The first half of 2022 has delivered both positive and negative developments for the Computer-Assisted Surgery industry. Supply chain issues and surges of COVID-19 infections have continued to have significant impacts on revenues. At the same time, enabling tech product launches proceed at a rapid pace, with some robotic procedures accelerating. The following is a sample of recent CAS news and developments from around the world, compiled by the expert analysts at SmartTRAK.

We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry. If you'd like to receive these expert insights daily, Contact Us to learn more.

New Products:

• Globus*
  

  GMED announced completion of the first clinical cases using Excelsius3D w/ the ExcelsiusGPS platform. The surgeries were completed at MedStar Union Memorial Hospital in MD, Northwest Specialty Hospital in ID & NYU Langone Health in NY.

• SeaSpine*

  SPNE touted the Q122 limited commercial launch of FLASH Navigation Lumbar Facet Fusion, which facilitates delivery of OsteoStrand Plus DBM Fiber pellets in spine MIS procedures. It is SPNE’s first procedural solution w/ integrated 7D technology. SPNE Q122 Earnings Press Release